Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation
Authors:
- Şeyma ÖzdenŞÖŞeyma Özden
- Fatma Merve TepetamFTFatma Merve Tepetam
- Yunus BozkurtYBYunus Bozkurt
- Fatma Terzioğlu ŞahinFŞFatma Terzioğlu Şahin
- Aysun AynacıAAAysun Aynacı
- Hasan Furkan AvcıHAHasan Furkan Avcı
- Mazlum DursunMDMazlum Dursun
- Mustafa Asım DemirkolMDMustafa Asım Demirkol
- Nihal YıldırımNYNihal Yıldırım
Open Access
- 5 January 2026
- journal article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 187 (4) , 385-391
Abstract
Introduction: Benralizumab, an anti-IL-5 receptor monoclonal antibody, induces near-complete eosinophil depletion and has demonstrated significant clinical benefits in severe eosinophilic asthma (SEA). Real-world data remain essential for evaluating its effectiveness outside controlled trial settings. The aim of the study was to assess the clinical, laboratory, and functional outcomes of benralizumab over 32 weeks in a real-life cohort of SEA patients in Türkiye, following its recent national approval. Methods: This retrospective study included biologic-naïve adults with SEA who initiated benralizumab between November 2023 and February 2025 and completed at least six consecutive doses. Peripheral blood eosinophil count (PBEC), clinically significant exacerbations (CSEs), Asthma Control Test (ACT) scores, and spirometric parameters were evaluated at baseline and week 32. Patients were classified as responders (ACT ≥20 and no CSE) or nonresponders. Results: Twenty-four patients (66.7% female; mean age 50.9 ± 13.1 years) were included. Median PBEC decreased from 800 (230–2,200) to 0 (0–100) cells/µL (p < 0.001). Median annual CSE frequency declined by 67% (p < 0.001). ACT scores improved from 9 (5–24) to 22 (9–25) (p < 0.001). Mean forced expiratory volume in 1 s (FEV1) increased from 1,719 ± 768 mL to 2,165 ± 831 mL (p < 0.001), while forced vital capacity (FVC) showed significant improvement. Forced expiratory flow between 25% and 75% of the FVC (FEF25–75) exhibited a nonsignificant trend toward increase. Sixteen patients (66.7%) were classified as responders. Responders had higher baseline PBEC, FEV1, and FEF25–75 values. Benralizumab was well tolerated, with only two mild adverse events observed. Conclusion: Benralizumab provided substantial improvements in eosinophilic inflammation, exacerbation frequency, symptom control, and lung function over 32 weeks in a real-life SEA cohort. These findings support benralizumab as an effective and well-tolerated therapeutic option in routine clinical practice.Keywords
This publication has 20 references indexed in Scilit:
- Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm studyThe Lancet Respiratory Medicine, 2022
- Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 YearsThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Benralizumab: First Global ApprovalDrugs, 2018
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe AsthmaNew England Journal of Medicine, 2017
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet, 2016
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2016
- The prevalence of severe refractory asthmaJournal of Allergy and Clinical Immunology, 2015
- Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophiliaJournal of Allergy and Clinical Immunology, 2013
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJournal of Allergy and Clinical Immunology, 2010
- Asthma exacerbations and sputum eosinophil counts: a randomised controlled trialThe Lancet, 2002